As specialty drug costs continue to rise, plan sponsors are seeking effective cost-control strategies, including specialty pharmacy carve-out programs. While the potential savings can be appealing, cost is only one of several factors employers should consider when evaluating whether a carve-out fits their benefits strategy. Milliman’s research examines both the net cost and key qualitative considerations, supported by a real-world employer case study highlighting issues to assess before implementation.